Background::Endocrine therapy (ET) and ET-based regimens are the preferred first-line treatment options for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HR+/HER2- MBC), while chemotherapy (CT) is commonly used in clinical practice. The aim of this study was to investigate the efficacy and clinical outcome of ET and CT as first-line treatment in Chinese patients with HR+/HER2- MBC.Methods::Patients diagnosed with HR+/HER2-MBC between January 1st, 1996 and September 30th, 2018 were screened from the Chinese Society of Clinical Oncology Breast Cancer database. The initial and maintenance first-line treatment, progression-free survival (PFS), and overall survival (OS) were analyzed.Results::Among the 1877 included patients, 1215 (64.7

作者：Yuan Yang；Zhang Shaohua；Wang Tao；Bian Li；Yan Min；Yin Yongmei；Song Yuhua；Wen Yi；Li Jianbin；Jiang Zefei

来源：中华医学杂志英文版 2023 年 136卷 12期